Clovis Oncology Inc (CLVS.OQ)
11 Mar 2014
|Market Cap (Mil.):||$2,775.36|
|Shares Outstanding (Mil.):||33.90|
Nov 19 - Clovis Oncology Inc : * Acquires EOS (Ethical Oncology Science) S.P.A. to gain rights to Lucitanib, a
Sept 25 - U.S. stocks edged up at the open on Wednesday, following four days of losses on the S&P 500 and Dow, even as a lack of progress in budget negotiations in Washington left investors puzzled. The Dow Jones industrial average was up 0.08 percent, the S&P 500 was up 0.05 percent and the Nasdaq Composite was up 0.12 percent.
- Clovis Oncology , a developer of cancer drugs that had been looking for a potential buyer, is finding no takers, according to a report by Bloomberg, citing a person with knowledge of the matter.
Sept 24 - Clovis Oncology, a developer of cancer drugs that had been looking for a potential buyer, is finding no takers, according to a report by Bloomberg, citing a person with knowledge of the matter.
- Clovis Oncology Inc , a cancer-focused drugmaker, is considering selling itself, three people familiar with the deal told Reuters this week.
Sept 17 - Clovis Oncology Inc, a cancer-focused drugmaker, is considering selling itself, three people familiar with the deal told Reuters this week.
|Eisai Co., Ltd (4523.T)||¥4,085||-22.00|
|Pfizer Inc. (PFE.N)||$32.42||+0.03|
|AstraZeneca plc (AZN.L)||3,973.50p||-42.50|
|BioMarin Pharmaceutical Inc. (BMRN.OQ)||$77.45||+0.25|
|Ariad Pharmaceuticals, Inc. (ARIA.OQ)||$7.69||-0.09|
|Abbott Laboratories (ABT.N)||$39.71||-0.11|
|TESARO Inc (TSRO.OQ)||$30.37||-0.20|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: Pechala's Reports
Clovis Oncology Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.